Moderna to apply for FDA emergency use authorization for COVID-19 vaccine candidate
Following analysis of additional primary efficacy data for its mRNA-1273 COVID-19 vaccine candidate, Moderna Inc. today said it will apply for emergency use authorization from the Food and Drug Administration; a review of its safety and efficacy package is scheduled for Dec. 17. Moderna said that its candidate showed 94.1% efficacy against COVID-19, with a 100% efficacy against severe cases. In the event of approval, it is expected that 20 million mRNA-1273 doses will be available in the U.S. by the end of 2020, with a total of 500 million to 1 billion doses available globally in 2021.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…